Topical product licensing opportunities

Solaraze® is a topical gel product for actinic keratosis that was developed by Skyepharma using its proprietary technologies. The product is marketed in the US by Sandoz and in Europe and certain other territories by Almirall. It is available for licensing in a limited number of other countries.

Solaraze (topical diclofenac) was developed by Skyepharma

Partners: Fougera Pharmaceuticals Inc (Sandoz) and Almirall SA

Technology challenge

Diclofenac is a non-steroidal anti-inflammatory drug that is used for the symptomatic treatment of pain and inflammation. However, it does not readily cross the skin. The challenge was to develop an aesthetically acceptable formulation of diclofenac that would create a depot in the skin in sufficient quantities to exert a therapeutic effect for the treatment of actinic keratosis.

Skyepharma’s solution

We applied our proprietary hyaluronic acid technology to maximize the concentration of diclofenac in the upper layers of the skin in a cosmetically acceptable gel formulation.


The product has been approved in more than 15 countries where it is sold by our licensees Fougera Pharmaceuticals Inc (Sandoz) and Almirall SA, and offers patients an alternative to conventional therapies that can be painful or disfiguring.

It is available for licensing in a limited number of other countries.

Please contact us to discuss availability.

Skyepharma has out-licensed the remainder of its topical technologies to focus on oral and inhalation technologies.

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.